ストックスクリーナーアプリを入手
48.66
3.71%
1.74
アフターアワーズ：
48.57
-0.09
-0.18%
前日終値:
$46.92
開ける：
$47.84
24時間の取引高:
15.51M
Relative Volume:
1.27
時価総額：
$215.18B
収益：
$50.91B
当期純損益:
$18.95B
株価収益率:
11.42
EPS:
4.261
ネットキャッシュフロー:
$1.92B
1週間 パフォーマンス:
+6.45%
1か月 パフォーマンス:
-0.23%
6か月 パフォーマンス:
+27.52%
1年 パフォーマンス:
-13.60%
1日の値動き範囲:
$47.56
$48.66
1週間の範囲:
$45.84
$48.66
52週間の値動き範囲:
$35.12
$64.16
Novo Nordisk Adr Stock (NVO) Company Profile
Compare NVO vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
48.66 | 204.03B | 50.91B | 18.95B | 1.92B | 4.261 |
LLY
Lilly Eli Co
|
1,233.66 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
273.14 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
265.79 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
156.45 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
159.98 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-26 | 開始されました | Wolfe Research | Peer Perform |
| 2026-03-18 | 開始されました | Bernstein | Outperform |
| 2026-03-10 | ダウングレード | TD Cowen | Buy → Hold |
| 2026-03-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2026-03-02 | ダウングレード | Goldman | Buy → Neutral |
| 2026-02-24 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2026-02-24 | ダウングレード | Kepler | Buy → Hold |
| 2026-02-23 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2026-02-12 | アップグレード | Jefferies | Underperform → Hold |
| 2026-01-27 | 開始されました | Citigroup | Neutral |
| 2025-12-08 | ダウングレード | Argus | Buy → Hold |
| 2025-10-27 | 再開されました | Jefferies | Underperform |
| 2025-10-01 | アップグレード | HSBC Securities | Hold → Buy |
| 2025-09-29 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | アップグレード | Berenberg | Hold → Buy |
| 2025-09-16 | アップグレード | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | アップグレード | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | ダウングレード | UBS | Buy → Neutral |
| 2025-07-31 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-07-30 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-04-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | アップグレード | Kepler | Hold → Buy |
| 2025-03-03 | ダウングレード | Stifel | Buy → Hold |
| 2025-02-12 | 開始されました | Morgan Stanley | Equal-Weight |
| 2025-01-06 | アップグレード | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-04-12 | 開始されました | BMO Capital Markets | Outperform |
| 2024-01-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-16 | 再開されました | UBS | Neutral |
| 2023-12-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-02 | 開始されました | Argus | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2022-07-15 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | ダウングレード | UBS | Neutral → Sell |
| 2022-06-27 | アップグレード | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-05-31 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-04-25 | アップグレード | Cowen | Market Perform → Outperform |
| 2022-04-12 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-01-25 | ダウングレード | Liberum | Hold → Sell |
| 2021-12-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-12-17 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2021-01-20 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-07-06 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-05-11 | ダウングレード | UBS | Buy → Neutral |
| 2020-05-04 | 開始されました | Cowen | Market Perform |
| 2020-03-16 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-11-18 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-09-17 | アップグレード | Citigroup | Neutral → Buy |
| 2019-08-30 | ダウングレード | Jefferies | Hold → Underperform |
| 2019-06-20 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2019-06-11 | アップグレード | Barclays | Underweight → Equal Weight |
| 2019-04-29 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | 開始されました | Exane BNP Paribas | Outperform |
| 2018-12-11 | 再開されました | Jefferies | Hold |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2017-12-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2017-12-06 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | アップグレード | BofA/Merrill | Underperform → Neutral |
すべてを表示
Novo Nordisk Adr (NVO) 最新ニュース
NVO Stock Quote Price and Forecast - CNN
Novo Nordisk stock firms as new Wegovy pill study follows raised 2026 outlook - Ad-hoc-news.de
Novo Nordisk Shares (NYSE:NVO) Gain 1.9% as $50 Medicare Wegovy Access Trial Challenges Pricing - ts2.tech
Novo Nordisk stock steadies after Q2 growth as buyback milestone is reached - Ad-hoc-news.de
Novo Nordisk stock benefits as France moves to reimburse Wegovy and new obesity trial begins - Ad-hoc-news.de
Novo Nordisk stock holds gains as obesity drug coverage in France supports long-term demand - Ad-hoc-news.de
Novo Nordisk A/Sshare repurchase programme - Finansavisen
Novo Nordisk stock steadies after Q2 2026 guidance raise and obesity pill volatility - Ad-hoc-news.de
Weekly Recap: Berenberg cuts NOVO_B and court orders Sun Pharma approval - TradingView
Novo Nordisk (NVO) Sues A Rival Over Obesity Drug Advertising Claims - Sahm
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger - The Motley Fool
Novo Nordisk stock slips as obesity battle with Lilly and broker downgrade weigh on valuation - Ad-hoc-news.de
Novo Nordisk stock slips after Berenberg downgrade as guidance and competition reshape the outlook - Ad-hoc-news.de
ETFs Investing in Novo Nordisk A/S Sponsored ADR Class B Stocks - TradingView
Why Does Novo Nordisk (NYSE:NVO) Matter to S&P 500 Healthcare? - Kalkine Media
Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule - Sahm
EBITDA per share of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVO.CI - TradingView
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B Revenue Breakdown – BCBA:NVO.CI - TradingView
Preferred dividends of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVO.CI - TradingView
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B - TradingView
Novo Nordisk NVO: $47.26 After Guidance Raise, Bull $64 - FinanceFeeds
Novo Nordisk Share Price Forecast | Q2 Earnings, Raised Guidance - Capital.com
Novo Nordisk's Track Record of Internal Innovation Supports a Wide Moat, but Diversification Needed - Morningstar
Novo Nordisk (CPH:NOVO-B; NYSE:NVO) ADR drops after Q2 results outpace forecasts, paving way for possible rebound in Copenhagen - TechStock²
Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook - Finansavisen
Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026 - Finansavisen
Novo Nordisk (NYSE: NVO) updates DKK 7,533,256,457 share repurchases - Stock Titan
Weight loss stock wars: Key metrics to watch in Eli Lilly and Novo Nordisk results - Investing.com
Novo Nordisk (NYSE:NVO) Ziltivekimab Trial Fails In Late Stage Cardiovascular Study - Sahm
European ADRs Slipped In US Trading Friday Morning - Finimize
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation - Finansavisen
Novo Nordisk shares fall after ZEUS trial disappointment highlights 94% sales reliance - TechStock²
Novo Nordisk must face fraud lawsuit over CagriSema trial, judge rules - Investing.com
Novo Nordisk A/S Sponsored ADR Class B Revenue Breakdown – MUN:NOVA - TradingView
Europe’s US-Listed ADRs Edged Higher Late Friday Morning - Finimize
Market news - investments.halifax.co.uk
BR:N1VO34 Stock Latest News - TipRanks
Novo Nordisk Sues Eli Lilly Over Alleged Deceptive Weight Loss Drug Advertising - Sahm
Novo Nordisk A/S ADR (NVO-N) Stock Price and News - The Globe and Mail
Novo Nordisk (NYSE: NVO) reports 24,959,179 shares repurchased in 2026 programme - Stock Titan
Novo Nordisk's Steady Innovation in Diabetes and Obesity Have Created a Wide Moat - Morningstar
Novo Nordisk (NYSE:NVO) Wins EU Approval For Oral And Higher Dose Wegovy - Sahm
Novo Nordisk Adr (NVO) 財務データ
収益
当期純利益
現金流量
EPS
0.36%
1.38%
大文字化:
|
ボリューム (24 時間):